预约演示
POINT well made: Lantheus promises up to $2B for 2 of the biotech's cancer radiopharmaceutical therapies
2022-11-14
临床3期引进/卖出临床1期
Lantheus and POINT Biopharma will form joint steering committees for two assets to oversee clinical studies and regulatory filings.
Lantheus is pPOINT Biopharmaion upfront for a double bill of licenses for two of POINT Biopharma’s radiopharmaceutical oncology candidates, with another $1.8 billion tied up in biobucks.
Lantheuse agreements, POINT will continue to fund and complete its phase 3 SPLASHPOINT Biopharma002, a prostate-specific membrane antigen (PSMA)-targeting 177Lu-based radiopharmaceutical therapy for metastatic castration-resistant prostate cancer. After that, Lantheus will work with POINT to file the therapy for FDA approval.
The other candidate is PNT2003, a somatostatin receptor-targeted radioligand in development PNT2002troeprostate-specific membrane antigen (PSMA)-targetingacilitate completion of the ongoing Universitmetastatic castration-resistant prostate cancerle Lantheus wiLantheusre and submit the regulatory filings in the U.S.
For both assets, the twPNT2003niessomatostatin receptorring committees to oversee the clinical sgastroenteropancreatic neuroendocrine tumorsure they are ready for manufacturing and to hit the market. If approved, Lantheus has the rights to commerciaLantheush therapies worldwide.
Should the two assets secure FDA approval and then hit commercial milestones, POINT could be in line for up to $1.8 billion in biobucks plus royalties of 20% and 15% for PNT2002 and PNT2003, respectively.Lantheus
Lantheus has already seen sucFDAs commercializing the cancer diagnostic imaging agent Pylarify and Azedra, the first and only approved treatment for advanced vascular andPNT2002tumorPNT2003d pheochromocytoma and paraganglioma. This track record in the field of radiopharmaceuticals made the company an “ideal collaborator” for PNT2002 and PNT2003, POINT CEO Joe McCann, Ph.D., said in a Monday morning release.
Lantheusllaboration also immediately unlocks value forcancer, reduces the need for dilPylarifyndraiAzedrand enables us to focus on our pipeline of neadvanced vascular and nerve tumorscould bepheochromocytomafor tparagangliomarecision oncology," McCann added.PNT2002PNT2003
Outside of the licensing deal, POINT will continue to develop its phase 1 pan-cancer FAP-α asset called PNT2004, as well as PNT2001, an actinium-225 next-generation PSMA program that the company expects to enter the clinic next year.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。